Sweet Smell Of Success For Destiny's Anti-MRSA Nasal Gel
Stock Soars On Phase IIb Data
Executive Summary
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.